Jun 13, 2024 02:40AM
Jan 29, 2023 09:50PM
Jan 29, 2023 06:30PM
Jan 26, 2023 08:46PM
Jan 26, 2023 06:30PM
Jan 18, 2023 08:08AM
Jan 17, 2023 10:28PM Eisai Aims to Advance Gastrointestinal Cancer Treatment with Research Across Multiple Tumor Types at ASCO GI 2023
Jan 16, 2023 03:56AM
Jan 15, 2023 07:30PM
Jan 10, 2023 09:52PM
Jan 10, 2023 06:30PM
Jan 9, 2023 06:55AM
Jan 9, 2023 05:40AM
Jan 6, 2023 11:30PM Eisai Submits Supplemental Biologics License Application to FDA for Traditional Approval of LEQEMBI™ (lecanemab-irmb) for the Treatment of Alzheimer's Disease
Jan 6, 2023 02:31PM
Jan 6, 2023 02:30PM
Jan 6, 2023 02:30PM
Jan 6, 2023 02:30PM
Jan 6, 2023 02:10PM
Dec 22, 2022 06:45PM
Dec 19, 2022 09:01PM Eisai to Divest Rights for Anti-Epileptic Drug Fycompa (perampanel) CIII in United States to Catalyst Pharmaceuticals
Dec 1, 2022 08:08AM
Dec 1, 2022 05:09AM
Nov 29, 2022 08:33PM
Nov 29, 2022 07:50PM
Nov 29, 2022 07:50PM
Nov 20, 2022 08:50PM
Nov 20, 2022 06:30PM EISAI TO PRESENT FULL FINDINGS FROM LECANEMAB CONFIRMATORY PHASE 3 CLINICAL TRIAL (CLARITY AD) AND OTHER ALZHEIMER'S DISEASE RESEARCH AT THE 15TH CLINICAL TRIALS ON ALZHEIMER'S DISEASE (CTAD) CONFEREN
Oct 21, 2022 10:30AM
Sep 28, 2022 07:00AM
Sep 28, 2022 01:15AM
Sep 27, 2022 07:30PM
Sep 11, 2022 07:00PM
Sep 6, 2022 08:08AM
Sep 5, 2022 08:42PM Eisai Presents New Data From its Oncology Portfolio and Pipeline at ESMO Congress 2022
Aug 3, 2022 07:32PM
Aug 3, 2022 07:25PM
Jul 25, 2022 07:32PM
Jul 25, 2022 07:04PM
Jul 5, 2022 08:12PM
Jul 5, 2022 07:30PM
Jun 22, 2022 12:05AM Eisai Publishes Potential Economic Value of Investigational Lecanemab in Peer-Reviewed Neurology and Therapy Journal
May 27, 2022 08:08AM
May 26, 2022 10:49PM
May 9, 2022 09:23PM
May 9, 2022 07:31PM
Apr 26, 2022 07:31PM
Mar 21, 2022 08:21PM
Mar 21, 2022 07:30PM LATEST FINDINGS ON LECANEMAB - CLINICAL EFFICACY, ARIA RATES, BIOMARKERS RELATIONSHIP TO CLINICAL OUTCOMES AND DOSING REGIMENS - PRESENTED AT AD/PD™ 2022 ANNUAL MEETING
Mar 10, 2022 09:15PM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All